INTRODUCTION {#s1}
============

Coronary heart disease (CHD) is a multifactorial disorder resulting from the interaction between environmental and genetic factors \[[@R1]\]. Many genes that associate with CHD have been identified in recent years. In the treatment of CHD, percutaneous coronary intervention (PCI) is the main therapy. However, restenosis (RS) following coronary stenting is a disadvantage of this therapy \[[@R2]\]. Current studies suggest that there are associations between genetic factors and the development of CHD or RS after PCI \[[@R3], [@R4]\].

Current studies have documented the interaction between HO-1 gene polymorphisms and CHD or RS after PCI. HO-1 is a subtype of heme oxygenase (HO) which plays a key regulatory role in the synthesis and catabolism of bilirubin \[[@R5]\]. HO will be increased significantly when the body responds to oxidative stress. During the degradation of heme to biliverdin, HO plays an important role as a rate-limiting enzyme \[[@R6]\]. Recently, two loci of HO-1 gene have been identified to be associated with CHD or RS in different population \[[@R7], [@R8]\]. One is the (GT)n dinucleotide repeat length polymorphism, the other is the T(−413)A (rs2071746). Both loci are located in the HO-1 gene promoter region and influence serum HO-1 expression levels \[[@R8]\].

Although many studies on the relationship between these two loci and CHD have been carried out \[[@R9]--[@R20]\], the results are not conclusive. Some studies \[[@R9]--[@R16]\] have indicated that there is a positive correlation between the HO-1 (GT)n repeat length polymorphism and CHD, while other studies \[[@R17]--[@R20]\] have suggested that alterations in HO-1 expression play no obvious role in the pathogenesis of CHD. Several studies \[[@R22]--[@R23]\] have indicated that HO-1 genetic polymorphisms are associated with RS after PCI. However, the results of the subsequent studies \[[@R17], [@R24]--[@R26]\] do not support this result.

Based on these observations, two meta-analyses \[[@R27]--[@R28]\] related to this topic have been published. Qiao et al. \[[@R27]\] reported a positive correlation between genetic polymorphisms of HO-1 gene and CHD or RS after PCI. However, the meta-analysis from Rong et al. \[[@R28]\] do not support this results. Thus, the association of HO-1 gene polymorphisms with CHD or RS remains unclear. To clarify these associations, we performed an updated meta-analysis.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

There were 176 potentially relevant papers acquired from PubMed, Web of Science, the Cochrane Library, Wanfang and CNKI databases. Of these, we excluded 143 documents because of irrelevance to the aim of our study after reading the title and abstract. The remaining 33 documents were full-text reviewed, and 3 studies were excluded due to reported associations with diabetes \[[@R29]--[@R31]\]. Four studies were not case-control studies \[[@R32]--[@R35]\], 3 studies were excluded because the variable number tandem repeat was different \[[@R36]--[@R38]\], 2 studies were excluded because there was no genotype data or it was a review \[[@R39]--[@R40]\]. Furthermore, 2 papers were excluded because of their lack of relation to CHD risk but rather to cardiovascular disease prognosis \[[@R41]--[@R42]\]. Finally, our meta-analysis included 19 eligible studies \[[@R9]--[@R26]\]. Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"} listed the characteristics of each study. Finally, a total of 13 studies of the (GT)n repeat length polymorphism and 4 studies of the T(−413)A SNP with CHD were included. Six studies of the (GT)n repeat length polymorphism with RS were included. Because 4 papers included 2 studies, there were 23 studies included in final analysis.

###### Characteristics of included studies

  Reference                                Year   Population     Case        Control    Age (years)   Genotyping method   Selection criteria   HWE          VNTR Cut-Off(s) (≥)   NOS (☆)        Study design                                      
  ---------------------------------------- ------ -------------- ----------- ---------- ------------- ------------------- -------------------- ------------ --------------------- -------------- -------------- ------------ ----- ------ ---- --- ----
  **(GT)n polymorphism with CHD**                                **Total**   **Male**   **female**    **Total**           **Male**             **female**   **Case**              **Control**    ***P***                                           
  Chen et al.                              2014   East Asian     386         358        28            361                 300                  61           70±8                  68±8           \>0.05         PCR-RFLP     CHD   0.15   27   6   CC
  Chen et al.                              2012   East Asian     2298        1675       623           2298                1675                 623          60.10± 10.3           59.9± 10.2     0.62           CE           CHD   0.11   25   8   CC
  Endler et al.                            2004   Caucasian      180         130        50            211                 103                  108          57-72 (64)            48-67 (58)     0.13           PCR-SSP+CE   CHD   0.91   25   6   CC
  Funk et al.                              2004   Caucasian      399         187        212           398                 192                  206          59-78 (69)            40-59 (47)     \<0.05         PCR-SSP      CHD   0.90   25   6   CC
  Gregorek et al.                          2013   Caucasian      59          NA         NA            58                  NA                   NA           62-73 (69)            57-73 (64)     \>0.05         PCR-SSP      CHD   0.85   25   6   CC
  Han et al.                               2014   East Asian     110         71         39            107                 56                   51           63± 11                52±12          \<0.01         PCR-SSP      CHD   0.06   25   6   CC
  Kaneda et al.                            2002   East Asian     298         250        48            279                 173                  106          63± 0.5               58±0.7         \>0.05         PCR-SSP      CHD   0.32   27   8   CC
  Lüblinghoff et al.                       2009   Caucasian      2526        1891       635           693                 360                  333          63± 10                55±12          \>0.05         CE           CHD   0.73   25   7   CC
  MI in Endler et al.                      2004   Caucasian      258         199        59            211                 103                  108          53-71(60.5)           48-67 (58)     0.22           PCR-SSP+CE   MI    0.91   25   6   CC
  Schillinger et al.                       2002   Caucasian      70          51         19            62                  20                   42           62- 78                61-79          0.40           PCR-SSP+CE   CHD   0.15   25   6   CC
  Wang et al.                              2009   Middle Asian   287         177        110           190                 126                  64           58.42± 11.1           58.03± 10. 4   0.34           PCR-SSP      MI    0.82   27   7   CC
  Y. H. Chen et al.                        2008   East Asian     664         611        53            322                 264                  58           69± 9                 67±7           \>0.05         CE           CHD   0.49   27   8   CC
  Zhang et al.                             2010   East Asian     300         228        72            182                 106                  76           62.96± 12.1           64.23± 12.1    0.13           CE           CHD   0.98   25   7   CC
  **(GT)n polymorphism with restenosis**                                                                                                                                                                                                           
  Exner et al                              2001   Caucasian      23          NA         NA            73                  NA                   NA           60-72 (70)            63-72 (69)     0.10           PCR-SSP      CHD   0.02   25   7   CS
  Han et al.                               2014   East Asian     18          NA         NA            27                  NA                   NA           63±11                 52±12          \<0.01         PCR-RFLP     CHD   0.07   25   6   CS
  Klaus et al.                             2007   Caucasian      401         NA         NA            956                 NA                   NA           65.5± 10.8            66.2± 10.7     0.51           PCR-SSP      CHD   0.01   25   7   CS
  Schillinger et al.                       2004   Caucasian      95          NA         NA            183                 NA                   NA           61-78 (71)            66-78 (73)     0.37           PCR-SSP      CHD   0.58   25   7   CS
  Wijpkema et al.                          2006   Caucasian      324         NA         NA            2601                NA                   NA           NA                    NA             NA             PCR-SSP      CHD   0.17   25   6   CS
  Y. H. Chen et al.                        2003   East Asian     111         NA         NA            212                 NA                   NA           70±8                  68±9           0.07           CE           CHD   0.89   26   7   CS
  **T(−413)A polymorphism with CHD**                                                                                                                                                                                                               
  Lüblinghoff et al.                       2009   Caucasian      2526        1891       635           693                 360                  333          63±10                 55±12          \>0.05         PCR-RFLP     CHD   0.49   NA   7   CC
  MI in Ono et al.                         2004   East Asian     393         326        67            1972                946                  1026         58.4 ±0.6             59.9± 0.3      0.06           PCR-SSP      MI    0.04   NA   8   CC
  Ono et al.                               2004   East Asian     204         169        35            1972                946                  1026         59.7± 0.8             59.9± 0.3      0.07           PCR-SSP      CHD   0.04   NA   8   CC
  Zhang et al.                             2010   East Asian     200         168        32            120                 100                  20           61.17± 5.6            62.68± 6.1     0.23           PCR-RFLP     CHD   0.89   NA   7   CC

**Notes:** CC, case-control study; CS, Cohort study; VNTR, variable number tandem repeat; HWE, Hardy-Weinberg equilibrium; CHD, coronary heart disease; MI, myocardial infarction; NOS, Newcastle-Ottawa Scale; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; SSP, sequence-specific primers; CE, capillary electrophoresis.

###### Date characteristics of included studies

  Reference                                Year   Ethnicity      Case   Control                                                                 
  ---------------------------------------- ------ -------------- ------ --------- ------ ------ ------ ------ ------ ------ ------ ----- ------ ------
  **(GT)n polymorphism with CHD**                                                                                                               
  Chen et al.                              2014   East Asian     386    94        187    105    375    397    361    78     194    89    350    372
  Chen et al.                              2012   East Asian     2298   436       1268   594    2140   2456   2298   548    1187   563   2283   2313
  Endler et al.                            2004   Caucasian      180    12        74     94     98     262    211    16     83     112   115    307
  Funk et al.                              2004   Caucasian      399    39        180    180    258    540    398    46     177    175   269    527
  Gregorek et al.                          2013   Caucasian      59     7         35     17     49     69     58     10     29     19    49     67
  Han et al.                               2014   East Asian     110    10        46     54     66     154    107    7      56     44    70     144
  Kaneda et al.                            2002   East Asian     298    47        165    86     259    337    279    48     145    86    241    317
  Lüblinghoff et al.                       2009   Caucasian      2526   286       1070   1170   1642   3410   693    66     302    325   434    952
  MI in Endler et al.                      2004   Caucasian      258    13        106    139    132    384    211    16     83     112   115    307
  Schillinger et al.                       2002   Caucasian      70     9         38     23     56     84     62     4      32     26    40     84
  Wang et al.                              2009   Middle Asian   287    57        128    102    242    332    190    55     93     42    203    177
  Y. H. Chen et al.                        2008   East Asian     664    147       322    195    616    712    322    74     167    81    315    329
  Zhang et al.                             2010   East Asian     300    39        145    116    223    377    182    27     86     69    140    224
  **(GT)n polymorphism with restenosis**                                                                                                        
  Exner et al                              2001   Caucasian      23     1         8      14     10     36     73     7      45     21    59     87
  Han et al.                               2014   East Asian     18     1         5      12     7      29     27     0      14     13    14     40
  Klaus et al.                             2007   Caucasian      401    45        155    201    245    557    956    109    370    477   588    1324
  Schillinger et al.                       2004   Caucasian      95     3         33     59     39     151    183    20     86     77    126    240
  Wijpkema et al.                          2006   Caucasian      324    151       151    22     453    195    2601   1256   1124   221   3636   1566
  Y. H. Chen et al.                        2003   East Asian     111    11        60     40     82     140    212    54     105    53    213    211
  **T(−413)A polymorphism with CHD**                                    AA        AT     TT     A      T             AA     AT     TT    A      T
  Lüblinghoff et al.                       2009   Caucasian      2526   893       1181   452    2967   2085   693    246    341    106   833    553
  MI in Ono et al.                         2004   East Asian     393    64        208    121    336    450    1972   420    930    622   1770   2174
  Ono et al.                               2004   East Asian     204    32        101    71     165    243    1972   420    930    622   1770   2174
  Zhang et al.                             2010   East Asian     200    40        137    23     217    183    120    28     80     12    136    104

Meta-analysis {#s2_2}
-------------

### HO-1(GT)n repeat length polymorphism and CHD {#s2_2_1}

First, we investigated the relation between HO-1(GT)n repeat length polymorphism and CHD. No significant heterogeneity was identified by H-test and I^2^ test in any of the genetic models (Table [3](#T3){ref-type="table"}), therefore, the fixed-effect model was used. Significant statistical association was found between HO-1(GT)n repeat length polymorphism and CHD risk under an allelic contrast (S vs. L, OR = 0.929, 95%CI = 0.881-0.978, P = 0.005), the recessive genetic model (SS vs. SL+LL, OR = 0.858, 95% CI = 0.780-0.945, P = 0.002), and the co-dominant genetic model (SS vs. LL, OR = 0.843, 95% CI = 0.754-0.942, P = 0.003). Comparing to SL+LL and LL genotypes carriers, the CHD risk was significantly decreased among the SS genotype patients (Figure [1](#F1){ref-type="fig"}--[5](#F5){ref-type="fig"}). However, we did not find significant association in the dominant genetic model (Table [4](#T4){ref-type="table"}).

###### heterogeneity test analysis -(GT)n repeat length polymorphism with CHD

  Study                       Heterogeneity test            
  --------------------------- -------------------- -------- -------
  Allele model(S/L)           1.21                 31.40%   0.132
  Recessive model(SS/SL+LL)   1.27                 38.30%   0.078
  Dominant model(SS+SL/LL)    1.07                 12.40%   0.320
  Co-dominant model(SL/LL)    1.01                 2.70%    0.420
  Co-dominant model(SS/LL)    1.25                 35.90%   0.096

![Meta-analysis of the relationship between the (GT)n polymorphism in the HO-1 gene and CHD risk for the allele model (S/L)](oncotarget-07-83437-g001){#F1}

![Meta-analysis of the relationship between the (GT)n polymorphism in the HO-1 gene and CHD risk for the recessive model (SS/SL+LL)](oncotarget-07-83437-g002){#F2}

![Meta-analysis of the relationship between the (GT)n polymorphism in the HO-1 gene and CHD risk for the dominant model (SS+SL/LL)](oncotarget-07-83437-g003){#F3}

![Meta-analysis of the relationship between the (GT)n polymorphism in the HO-1 gene and CHD risk for the co-dominant model (SL/LL)](oncotarget-07-83437-g004){#F4}

![Meta-analysis of the relationship between the (GT)n polymorphism in the HO-1 gene and CHD risk for the co-dominant model (SS/LL)](oncotarget-07-83437-g005){#F5}

###### Results From a Meta-Analysis of the Association Between coronary heart disease or restenosis after PCI and the Heme oxygenase-1 gene promoter polymorphism

  Polymorphism and Subgroup                No. of Studies   No. of Cases   No. of Controls   Genotype                                                                                                                                                           
  ---------------------------------------- ---------------- -------------- ----------------- ---------------------- ----------- ---------------------- ----------- ---------------------- ----------- ---------------------- ----------- ---------------------- -----------
  **(GT)n polymorphism with CHD**                                                                                                                                                                                                                               
  **Total**                                13               7835           5372              0.929(0.881, 0.978)    0.005       0.858(0.780, 0.945)    0.002       0.937 (0.867, 1.012)   0.100       0.963(0.888, 1.045)    0.369       0.843 (0.754, 0.942)   0.003
   **Caucasian**                           6                3492           1633              1.019 (0.927, 1.119)   0.701       1.033(0.840, 1.271)    0.759       1.020 (0.901, 1.154)   0.756       1.015(0.892, 1.156)    0.818       1.042(0.838, 1.296)    0.709
   **Asian**                               7                4343           3739              0.891 (0.837, 0.949)   0.000       0.815(0.731, 0.909)    0.000       0.887 (0.803, 0.980)   0.018       0.931(0.838, 1.034)    0.180       0.781(0.686, 0.890)    0.000
   **Good quality**                        6                6373           3964              0.915 (0.863, 0.971)   0.003       0.830 (0.746, 0.924)   0.001       0.929 (0.849, 1.017)   0.110       0.964(0.877, 1.060)    0.551       0.822(0.726, 0.930)    0.002
   **Poor quality**                        7                1462           1408              0.959 (0.856, 1.074)   0.468       0.995 (0.795, 1.246)   0.976       0.960 (0.824, 1.117)   0.595       0.961(0.819, 1.127)    0.623       0.935(0.728, 1.201)    0.599
  **(GT)n polymorphism with restenosis**                                                                                                                                                                                                                        
  **Total**                                6                972            4052              0.718 (0.541, 0.953)   0.022       0.674 (0.425, 1.069)   0.093       0.662(0.434, 1.010)    0.056       0.877(0.740, 1.039)    0.130       0.522(0.306, 0.889)    0.017
   **Caucasian**                           4                843            3813              0.766 (0.557, 1.053)   0.100       0.870 (0.637, 1.190)   0.384       0.694 (0.400, 1.204)   0.194       0.742 (0.439, 1.254)   0.265       0.72 (0.384, 1.380)    0.330
   **Asian**                               2                129            239               0.590 (0.430, 0.809)   0.001       0.755(0.065, 0.737)    0.022       0.572 (0.361, 0.907)   0.018       0.689 (0.426, 1.115)   0.130       0.548(0.461, 0.660)    0.003
   **Meeting HWE**                         4                548            3023              0.679(0.446, 0.934)    0.041       0.553(0.230, 1.327)    0.184       0.664(0.381, 1.156)    0.148       0.740(0.435, 1.258)    0.266       0.414(0.195, 0.879)    0.022
   **Deviating from HWE**                  2                424            1029              0.693(0.296, 1.620)    0.397       0.959(0.667, 1.380)    0.822       0.554(0.151, 2.034)    0.373       0.566(0.158, 2.209)    0.382       0.684(0.192, 2.434)    0.557
   **T(−413)A polymorphism with CHD**                                                        A/T                    AA/AT+TT    AA+AT/TT               AT/TT       AA/TT                                                                                        
  **Total**                                                                                  OR and 95%CI           *P* Value   OR and 95%CI           *P* Value   OR and 95%CI           *P* Value   OR and 95%CI           *P* Value   OR and 95%CI           *P* Value
                                           4                3323           4757              0.915(0.842, 0.995)    0.038       0.869(0.760, 0.994)    0.041       0.907(0.788, 1.045)    0.177       0.958(0.826, 1.110)    0.567       0.792(0.663, 0.946)    0.010

The second subgroup analysis was conducted according to ethnicity. The fixed-effects model was utilized to perform meta-analysis in all of the genetic models. We found patients with SS genotype have decreased CHD risk compared to SL+LL and LL genotype carriers in the Asian subgroup (S vs. L, OR = 0.891, 95% CI = 0.837-0.949, P = 0.000; SS vs. SL+LL, OR = 0.815, 95% CI = 0.731-0.909, P = 0.000; SS+SL vs. LL, OR = 0.887, 95% CI = 0.803-0.980, P = 0.018; SS vs. LL, OR = 0.781, 95% CI = 0.686-0.890, P = 0.000). However, this association was not observed in Caucasian populations (Table [4](#T4){ref-type="table"}).

In addition, we conducted subgroup analysis according to quality assessment. The fixed-effects model was used in all of the genetic models. Significantly decreased risk of CHD was found among individuals with the SS genotype compared to patients with L allele (SL + LL and LL genotypes) in the good-quality subgroup (S vs. L, OR = 0.951, 95% CI = 0.863-0.971, P = 0.003; SS vs. SL+LL, OR = 0.830, 95% CI = 0.746-0.924, P = 0.001; SS vs. LL, OR = 0.822, 95% CI = 0.726-0.930, P = 0.002). However, this association was not found in the poor-quality reports (Table [4](#T4){ref-type="table"}).

### HO-1(GT)n repeat length polymorphism and RS {#s2_2_2}

In 6 independent studies, drug-eluting stents were utilized. These studies examined the main baseline characteristics and identified no significant difference. First, significant heterogeneity was found in the contrast models, and therefore, the random-effects model was used in this meta-analysis. In the overall population, we found that patients with S allele had a decreased RS risk after PCI compared with the L allele carriers (S vs. L, OR = 0.718, 95% CI = 0.541-0.953, P = 0.022; SS vs. LL, OR = 0.522, 95% CI = 0.306-0.889, P = 0.017) (Figure [6](#F6){ref-type="fig"}--[7](#F7){ref-type="fig"}). However, we did not found significantly decreased risks of RS in other genetic models (SS vs. SL+LL, OR = 0.674, 95% CI = 0.425-1.069, P=0.093; SS+SL vs. LL, OR = 0.662, 95% CI = 0.434-1.010, P = 0.056; SL vs. LL, OR = 0.877, 95% CI = 0.740-1.039, P = 0.130). Second, subgroup analysis was conducted according to ethnicity. The RS risk was significantly decreased among patients with the SS genotype compared with other genotypes in the Asian subgroup (S vs. L, OR= 0.590, 95% CI = 0.430-0.809, P = 0.001; SS vs. SL+LL, OR = 0.755, 95% CI = 0.065-0.737, P = 0.022; SS+SL vs. LL, OR = 0.572, 95% CI = 0.361-0.907, P = 0.018; SS vs. LL, OR = 0.548, 95% CI = 0.461-0.660, P = 0.003). When we excluded the studies which were inconsistent with the HWE, the protective effects of the S allele for RS after PCI persisted (S vs. L, OR= 0.679, 95% CI = 0.446-0.934, P = 0.041; SS vs. LL, OR = 0.414, 95% CI = 0.195-0.879, P = 0.022) (Table [4](#T4){ref-type="table"}).

![Meta-analysis of the relationship between the (GT)n polymorphism in the HO-1 gene and RS after PCI for the allele model (S/L)](oncotarget-07-83437-g006){#F6}

![Meta-analysis of the relationship between the (GT)n polymorphism in the HO-1 gene and RS after PCI for the allele model (SS/LL)](oncotarget-07-83437-g007){#F7}

### HO-1 T(−413)A SNP and CHD risk {#s2_2_3}

There were 4 studies that investigated the relationship between the HO-1T(−413)A SNP and CHD. No significant heterogeneity was found in the contrast models, and so the fixed-effect model was used in this of meta-analysis. Meta-analysis suggested that there was a significant association between the HO-1 T(−413)A polymorphism and CHD under the allele contrast (A vs. T, OR = 0.915, 95% CI = 0.842-0.995, P = 0.038), the recessive genetic model (AA vs. AT+TT, OR = 0.869, 95% CI = 0.760-0.994, P = 0.041), and the co-dominant genetic model (AA vs. TT, OR = 0.792, 95% CI = 0.663-0.946, P = 0.010) (Table [4](#T4){ref-type="table"}).

Sensitivity analysis {#s2_3}
--------------------

We performed the sensitivity analysis to examine the influence of each study on the pooled ORs by deleting each study one at a time in each genetic model. The pooled ORs showed no significant change, suggesting the results are stable (Figure [8](#F8){ref-type="fig"}).

![Sensitivity analysis of the relationship between the (GT)n polymorphism in the HO-1 gene and CHD risk for the allele model](oncotarget-07-83437-g008){#F8}

Publication bias {#s2_4}
----------------

In the present study, we utilized Egger\'s test and funnel plots to evaluate the publication bias of all contrast models. By Egger\'s test and funnel plots, we did not found publication biases for both the (GT)n repeat length polymorphism and T(−413)A SNP (Table [5](#T5){ref-type="table"}, Figure [9](#F9){ref-type="fig"}).

###### Egg\'s test results

  Association                           Genetic model     *P* value
  ------------------------------------- ----------------- -----------
  (GT)n polymorphism and CHD            S versus L        0.598
                                        SS versus SL+LL   0.301
                                        SS+SL versus LL   0.823
                                        SL versus LL      0.975
                                        SS versus LL      0.519
  (GT)n polymorphism and RS after PCI   S versus L        0.068
                                        SS versus SL+LL   0.366
                                        SS+SL versus LL   0.127
                                        SL versus LL      0.133
                                        SS versus LL      0.142
  T(−413)A polymorphism and CHD         A versus T        0.395
                                        AA versus AT+TT   0.263
                                        AA+AT versus TT   0.820
                                        AT versus TT      0.909
                                        AA versus TT      0.370

![Funnel plot of the association between the (GT)n polymorphism in the HO-1 gene and CHD risk\
**A.** the allele model (S/L); **B.** the recessive model (SS/SL+LL); **C.** the dominant model (SS+SL/LL); **D.** the co-dominant model (SL/LL); **E.** the co-dominant model (SS/LL).](oncotarget-07-83437-g009){#F9}

DISCUSSION {#s3}
==========

The present study indicates that HO-1 gene polymorphisms are associated with CHD independently. There are three isoforms of heme oxygenase in human, including HO-1, HO-2 and HO-3. HO-1 is up-regulated by oxidative stress and its own substrate heme \[[@R43]\] and may be modulated by fragile histidine triad gene (*FHIT*) \[[@R44]\]. Animal experiments and clinical trials have confirmed that the HO-1 enzyme is expressed in various tissues and cells, including asatherosclerotic lesions and vascular smooth muscle cells \[[@R43]\]. Therefore, HO-1 is considered to provide protective functions against asatherosclerotic lesions formation \[[@R43]\] and cellular proliferation \[[@R45]\].

Recently, many studies have suggested that HO-1 gene polymorphisms were associated with CHD \[[@R9]--[@R20]\]. The SS genotype of the HO-1(GT)n locus may promote HO-1 gene expression and result in increased protein production, thereby raising bilirubin levels and so reducing the risk of CHD \[[@R9]--[@R16]\] and restenosis following coronary stenting \[[@R22], [@R23]\]. However, some studies have come to other conclusions. Theoretically, meta-analysis can clarify the conclusions. Unfortunately, the two previously published meta-analyses came to different conclusions. Recently several new publications focused on this topic have been published. We conducted an update meta-analysis to clarify the association of HO-1 polymorphisms with CHD and RS.

In the present study, a significant association of the (GT)n SS genotype or S allele with decreased the risk of CHD and RS after PCI was observed. In the subgroup analysis, the Asian population showed a positive association in the all genetic models, while the study conducted with the Caucasian population showed no significant association in any of the genetic models. This can be explained by the high prevalence of S allele in Asian subjects. In addition, because of difference in life styles, ethnicity, region, and other factors, there are large differences in gene distribution. Nevertheless, more studies have been included in the present meta-analysis, and all the included studies were of high quality according to the methodological quality assessment. No significant heterogeneity was identified, and supplementary analysis, including subgroup and sensitivity analysis, were performed to strengthen our conclusions.

The present study also shows an association between genetic factors and the risk of stenting RS. We found that the HO-1T(−413)A SNP was associated with decreased risk for CHD. However, this significant association should be interpreted cautiously. First, CHD or RS after PCI are complex diseases with multifactorial etiology, including gene and environmental factors. Only one SNP is not sufficient to provide the appropriate explanation of genetic risk for CHD or RS after PCI. Gene-gene or gene-environment interaction factors may influence the risk of a subject for CHD or RS. Second, some potentially confounding factors should be discussed. Primary sources of heterogeneity include the following: the condition of the population included in this study, the main characteristics of the stents following PCI and the treatment compliance of the patients. In addition, the number of included studies for the HO-1T(−413)A SNP is small, and so we did not perform further subgroup analysis in the present study. Even so, the conclusion still give us some information on the pathogenesis of CHD and RS risk factors. Indeed, HO-1 is involved in the occurrence of restenosis by inhibiting vascular smooth muscle cells, attenuating vascular remodeling, and other mechanisms \[[@R48], [@R49]\]. Although in our meta-analysis, we found that S allele carriers have decreased risk for RS after PCI compare with L allele carriers and that the HO-1 T(−413)A SNP was associated with decreased risk of CHD, the importance of HO-1 in human RS following coronary stenting has not been fully defined.

Several limitations of our study need to be considered. First, the number of included studies for HO-1T(−413)A SNP is small, and so we did not perform further subgroup analyses in the present study. Second, limiting the included studies to those published in English and Chinese might have missed some eligible studies in other languages. In addition, it is possible that the results included in the present meta-analysis are affected by miscounting the genotypes or misclassification of CHD and RS.

Hence, our results suggested that carrying the S allele of the (GT)n locus or the A allele of the T(−413)A locus in the HO-1 gene promoter decreased the risk of CHD. We also found that carrying shorter (GT)n repeats (S or SS genotype) but not the T(−413)A SNP was associated with decreased risk of RS after PCI. These effects appeared more significant in Asian populations.

MATERIALS AND METHODS {#s4}
=====================

Identification of eligible studies {#s4_1}
----------------------------------

We carried out a systematic search in PubMed, Web of Science, the Cochrane Library, Wanfang Data and CNKI (China National Knowledge Infrastructure), with the last search updated on February 1, 2016. The following terms were used: "heme oxygenase 1" or "HO-1" or "HMOX-1" and "polymorphism" and "coronary artery disease" or "cardiac heart disease" or "myocardial infarction" or "MI" or "angina pectoris" or "arteriosclerosis" or "coronary disease" or "acute coronary syndrome" or "coronary stenosis" or "restenosis" or "stent-restenosis". We included literature on relevant studies carried out in human subjects published in English and Chinese. CHD was defined as confirmed myocardial infarction, typical angina pectoris (by the World Health Organization criteria), or a history of PCI or as diagnosed by angiography. The controls were defined as in-patients, outpatients, or members of the general population who were without typical angina pectoris or electrocardiographic abnormality and without coronary artery stenosis of more than 20% upon coronary angiography \[[@R28]\].

Inclusion criteria {#s4_2}
------------------

The studies in our meta-analysis met the following inclusion criteria: (1) case-control or cohort studies; (2) investigation of the association between the HO-1 gene polymorphisms and coronary artery disease or coronary restenosis; (3) inclusion of all patients, which were using drug-eluting stents(DES) and had 6 months follow-up angiography, after stenting (Restenosis, was defined as angiographic restenosis, diameter stenosis of \>50%, and clinical restenosis, target vessel revascularization during the follow-up.);(4) studies focusing on humans; and (5) unabridged genotype data could be acquired to calculate the odds ratios (ORs) and 95% confidence intervals (CIs).

Exclusion criteria {#s4_3}
------------------

We excluded papers according to the following criteria: (1) studies with no genotype data; (2) commentaries, reviews and editorials; (3) family-based studies of pedigrees; and (4) repeated studies using the same population data or duplicated data.

Data extraction {#s4_4}
---------------

Data collection from the eligible studies were conducted independently by two investigators (Zhang and Zheng). The following contents were collected: name of the first author, year of publication, ethnicity or geographic location of the study subjects, the characteristics of cases and controls, genotyping methods, number of cases and controls, the criteria for cases and controls, genotype frequency in cases and controls for HO-1 genotypes, Hardy--Weinberg equilibrium, and type of stents. Two investigators checked the extracted data and reached a consensus on all the data. If a disagreement existed, a third investigator (Xie) would adjudicate the disagreement.

Quality assessment {#s4_5}
------------------

To determine the methodological quality of each study, we used the Newcastle-Ottawa scale (NOS), which uses a "star" rating system to judge the quality of all included studies. The NOS ranges between zero (worst) and nine stars (best). Studies with a score equal to or higher than seven were considered to be of good quality. A score equal to or higher than four and less than seven was regarded as being poor quality. Two investigators (Zheng and Zhang) independently assessed the quality of included studies, and the results were reviewed by a third investigator (Xie). Disagreement was resolved by discussion.

Statistics analysis {#s4_6}
-------------------

Stata 12.0 software (StataCorp, College Station, TX, USA) was used for statistical analysis in our meta-analysis. The Hardy--Weinberg equilibrium (HWE) was calculated for each study using the Chi-square test in control groups, and P \< 0.05 was considered a significant deviation from the HWE. Odds ratios and 95% confidence intervals were calculated to assess the strength of the associations of the polymorphism and susceptibility to CHD or RS risk. The associations between the genetic variant and CHD or RS risk of pooled ORs were performed for allelic comparison \[(GT) n: S vs. L; T(−413)A: A vs. T\], a recessive genetic model \[(GT) n: SS vs. SL+LL; T(−413)A: AA vs. AT+TT\], a dominant model \[(GT) n: SS+SL vs. LL; T(−413)A: AA+AT vs. TT\], and a co-dominant model \[(GT) n: SL vs. LL, SS vs. LL; T(−413)A: AT vs. TT, AA vs. TT\]. The statistically significant level was determined by Z-test, and significance was set at *p*\<0.05. Heterogeneity was assessed using the H test (significance level of *P*\< 0.1) and the I^2^ test (greater than 50% as evidence of significant inconsistency). Pooled effect sizes were determined using a fixed-effects model (the Mantel--Haenszel method) when heterogeneity was negligible (I^2^\<50%) or a random-effects model (the DerSimonian and Kacker method) when significant heterogeneity was present (I^2^≥50%). We also performed a sensitivity analysis to evaluate the effect of each study on the combined ORs by omitting each study in turn. Finally, we utilized Egger\'s tests to assess the potential publication bias.
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